TD Cowen began coverage of Soleno Therapeutics with a Buy rating on June 27, 2025.
1 report, 0 independent
Updated Jun 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen began coverage of Soleno Therapeutics with a Buy rating on June 27, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Soleno Therapeutics (United States)
company in Redwood City, United States
Related events
- TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.
- TD Cowen, Stephens, Citigroup, and MarketBeat provided new analyst ratings and coverage for Covenant Logistics Group, Inc.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
Coverage
Newest first; wire copies grouped- Unknown outlet